TrialLeukemia & lymphoma2014

A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.

Craig S Sauter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.